1. Home
  2. ADSE vs ANNX Comparison

ADSE vs ANNX Comparison

Compare ADSE & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADS-TEC ENERGY PLC

ADSE

ADS-TEC ENERGY PLC

N/A

Current Price

$11.18

Market Cap

900.0M

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$4.86

Market Cap

873.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADSE
ANNX
Founded
1980
2011
Country
Ireland
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
900.0M
873.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ADSE
ANNX
Price
$11.18
$4.86
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
15.8K
2.4M
Earning Date
05-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$549.86
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.89
$2.13
52 Week High
$13.50
$7.18

Technical Indicators

Market Signals
Indicator
ADSE
ANNX
Relative Strength Index (RSI) 41.58 40.86
Support Level $10.98 $4.72
Resistance Level $12.02 $5.63
Average True Range (ATR) 0.39 0.26
MACD -0.01 -0.03
Stochastic Oscillator 28.57 7.41

Price Performance

Historical Comparison
ADSE
ANNX

About ADSE ADS-TEC ENERGY PLC

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: